Hikma joins Ergomed for cancer drug trials
Hikma Pharmaceuticals has initiated a partnership agreement with Ergomed, an international provider of drug development services.
Under the agreement, Ergomed will be conducting the first clinical trials for one of Hikma's key oncology (anti-cancer) products in Jordanian hospitals with plans of potential expansion in the Mena region.
Ergomed will manage clinical trials of Hikma treatments in a pilot project in Jordan, and in turn, Hikma will provide Ergomed with an expanded insight into the regional pharmaceutical sector.
Hikma Pharmaceuticals CEO Said Darwazah said their work with Ergomed supports the company's commitment in medical advancement through the use of clinical trials, especially in the field of oncology.
Hikma Pharmaceuticals is focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in licensed products.
Related Insight
Suppliers Directory
C3 Research Associates - Clinical Research Development and Management Group
C3 Research Associates is a quality-focused clinical research development and management group supporting innovative biotechnology, medical device and pharmaceutical organizations, stewarding therapeutics from preclinical through phase IV drug development and successful market life cycle.
Suppliers
Chemetall - Tools for Organic Synthesis
Chemetall is a global company committed to specialty chemistry. The Lithium Division of Chemetall is the world’s leading supplier of Lithium compounds. Following to our expertise in this field of chemistry we also supply other organometallic compounds such as Grignard reagents, Amides and Alkoxides.
Suppliers
SCA Cool Logistics - Temperature Controlled Packaging Solutions
SCA Cool Logistics International Group designs, qualifies, manufactures and supplies temperature controlled packaging solutions focusing predominantly, on Pharmaceutical, Biotech, and Clinical Research industries.
Suppliers
Vaisala - Measurement Instruments and Continuous Monitoring System for Critical Environments in Life Science and High-Technology
Vaisala is a global leader in environmental and industrial measurement.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Right Place, Right Time
Published by Centrical Global Limited
White Papers
Pipet Controller for Graduated, Volumetric and Blow-out Pipettes
Published by VITLAB®
White Papers
SynBiosys™ Drug Eluting Stent Coating
Published by InnoCore Technologies BV
White Papers
Outsourcing Best Practices
Published by Medpace
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.